Gypensapogenin I ameliorates liver fibrosis by targeting MST1, restoring Hippo pathway homeostasis, and inhibiting HSCs activation

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Gypensapogenin I (GI) is a new dammarane type triterpenoid saponin extracted from Gynostemma pentaphyllum. This study explored the therapeutic potential and mechanism of GI on liver fibrosis (LF). LF is a key pathological stage of chronic liver disease, and the current treatment is limited. In the mouse LF model induced by carbon tetrachloride (CCl₄) and the LX-2 hepatic stellate cell model activated by transforming growth factor-β1 (TGF-β1), GI showed significant antifibrotic effects in vitro and in vivo, and could reduce liver injury, inflammation, collagen deposition and cell activation. Mechanistic studies have shown that GI exerts its effect by directly targeting MST1 protein. The direct and specific interaction between GI and MST1 was confirmed by surface plasmon resonance (SPR), drug affinity reaction target stability (DARTS) and cell thermal transition analysis (CETSA). Site directed mutagenesis further identified Arg181 as a key residue necessary for the stable binding of GI to MST1. This binding activated the Hippo signaling pathway, promoted the phosphorylation of MST1, LATS1/2 and YAP, resulting in the retention and inactivation of YAP in the cytoplasm. More importantly, after knockdown ofSTK4 gene encoding Mst1 by siRNA, the antifibrotic effect of GI was completely abolished, thus establishing MST1 as its essential functional target. In summary, this study found that GI is a novel MST1 agonist, which alleviates LF by targeting Arg181 residue, restoring Hippo/YAP pathway homeostasis and inhibiting hepatic stellate cell activation, which makes GI a promising candidate drug in the treatment of LF.

Keywords

Gypensapogenin I / Liver fibrosis / HSCs activation / MST1 / Hippo pathway

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Lambrecht J, Mannaerts I, van Grunsven LA . The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis. Front Physiol. 2015; 6:209. https://doi.org/10.3389/fphys.2015.00209.

[2] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019; 70:151-171. https://doi.org/10.1016/j.jhep.2018.09.014.

[3] Ren S, Chen JM, Wang QL, et al. MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis. Hepatol Int. 2019; 13:814-825. https://doi.org/10.1007/s12072-019-09993-w.

[4] Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4:2823. https://doi.org/10.1038/ncomms3823.

[5] Lee EJ, Hwang I, Lee JY, et al. Hepatic stellate cell-specific knockout of transcriptional intermediary factor 1 gamma aggravates liver fibrosis. J Exp Med. 2020; 217. https://doi.org/10.1084/jem.20190402

[6] Hazra S, Xiong SG, Wang JH, et al. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem. 2004; 279:11392-11401. https://doi.org/10.1074/jbc.M310284200.

[7] Cubero FJ . Shutting off inflammation: a novel switch on hepatic stellate cells. Hepatology. 2016; 63:1086-1089. https://doi.org/10.1002/hep.28442.

[8] Driskill JH, Pan D . The Hippo pathway in liver homeostasis and pathophysiology. Annu Rev Pathol. 2021; 16:299-322. https://doi.org/10.1146/annurev-pathol-030420-105050.

[9] Yu FX, Guan KL . The Hippo pathway: regulators and regulations. Genes Dev. 2013; 27:355-371. https://doi.org/10.1101/gad.210773.112.

[10] Wang X, Freire Valls A, Schermann G, et al. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Dev Cell. 2017; 42:462-478.e7. https://doi.org/10.1016/j.devcel.2017.08.002.

[11] Parola M, Pinzani M . Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019; 65:37-55. https://doi.org/10.1016/j.mam.2018.09.002.

[12] Yuan ZY, Xie MZ, Huang HY . Research progress on plant resources, chemical constituents, and pharmacological effects of Gynostemma pentaphyllum . Asia-Pacific Tradit Med. 2019; 15:190-197. https://doi.org/10.11954/ytctyy.201907063.

[13] Bai H, Wang Y, Ge W, et al. Research progress on the anticancer mechanism of isoflavone saponins. Northwest J Pharm. 2019; 34:564-567. https://doi.org/10.3969/j.issn.1004-2407.2019.04.034.

[14] Shen Z, Wang Z, Hou H . New advances in the study of chemical composition, pharmacological effects and application of isoflavones. Ginseng Res. 2020; 32:59-64. https://doi.org/10.19403/j.cnki.1671-1521.2020.04.014.

[15] Li C, Zhang R, Zhan Y, et al. Resveratrol inhibits hepatic stellate cell activation via the hippo pathway. Mediators Inflamm. 2021; 2021:3399357. https://doi.org/10.1155/2021/3399357.

[16] Philipp S, Sarah N, Katja L, et al. PLIP 2025: introducing protein-protein interactions to the protein-ligand interaction profiler. Nucleic Acids Res. 2025; 53:463-465. https://doi.org/10.1093/nar/gkaf361.

[17] Tsuchida T, Friedman SL . Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14:397-411. https://doi.org/10.1038/nrgastro.2017.38.

[18] Fabregat I, Moreno-Càceres J, Sánchez A, et al. TGF-β signalling and liver disease. FEBS J. 2016; 283:2219-2232. https://doi.org/10.1111/febs.13665.

[19] Fan F, He Z, Kong LL, et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med. 2016; 8:352ra108. https://doi.org/10.1126/scitranslmed.aaf2304.

[20] Kim CL, Choi SH, Mo JS . Role of the Hippo pathway in fibrosis and cancer. Cells. 2019; 8:468. https://doi.org/10.3390/cells8050468.

[21] Wang X, Zheng Z, Caviglia JM, et al. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in hepatocyte TAZ/WWTR1. Cell Metab. 2016; 24:848-862. https://doi.org/10.1016/j.cmet.2016.09.016.

[22] Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130:1120-1133. https://doi.org/10.1016/j.cell.2007.07.019.

[23] Tu K, Yang W, Li C, et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014; 13:110. https://doi.org/10.1186/1476-4598-13-110.

[24] Park S, Kim J, Yang S, et al. Exogenous S1P via S1P receptor 2 induces CTGF expression through Src-RhoA-ROCK-YAP pathway in hepatic stellate cells. Mol Biol Rep. 2024; 51:950. https://doi.org/10.1007/s11033-024-09868-w.

[25] Hernandez-Gea V, Friedman SL . Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011; 6:425-456. https://doi.org/10.1146/annurev-pathol-011110-130246.

[26] Li N, Wu CF, Xu XY, et al. Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum . Eur J Med Chem. 2012; 50:173-178. https://doi.org/10.1016/j.ejmech.2012.01.052.

[27] Yasuda D, Kobayashi D, Akahoshi N, et al. Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing Notch ligand Dll4. J Clin Invest. 2019; 129:4332-4349. https://doi.org/10.1172/jci121955.

[28] Zhang K, Chang Y, Shi Z, et al. Omega-3 PUFAs ameliorate liver fibrosis and inhibit hepatic stellate cells proliferation and activation by promoting YAP/TAZ degradation. Sci Rep. 2016; 6:30029. https://doi.org/10.1038/srep30029

[29] Song H, Li J, Yang H, et al. Enhancement of functional insulin-producing cell differentiation from embryonic stem cells through MST1-silencing. Diabetol Metab Syndr. 2025; 17:93. https://doi.org/10.1186/s13098-025-01666-z.

[30] Lee JH, Guo Z, Myler LR, et al. Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One. 2014; 9(6):e97969. https://doi.org/10.1371/journal.pone.0097969.